Frontotemporal dementia with parkinsonism is one of the major degenerative dementia syndromes (Table 1) , particularly for those who begin experiencing cognitive, behavioral, or motor changes before age 65 years. Advances in immunocytochemistry and molecular genetics have greatly expanded our knowledge of the disorders (and their associated dysfunctional proteins) that can manifest as dementia with or without parkinsonism ( Table 2) . No disease-altering treatment has been identified as yet for any of the neurodegenerative disorders that can manifest clinically as FTDP ( Table 2 ). The development of potential therapies requires knowledge about the pathophysiology of the varying disorders. The identification of causative genes offers opportunities to quickly learn about the pathophysiologic processes involved in neurodegeneration, and drug testing can proceed relatively quickly using transgenic mouse models that are designed to mimic the human disease. Several groups of investigators have focused on families carrying mutations that cause FTDP.
The hunt for causative genes in FTDP was largely spearheaded by the first Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 Consensus Conference in Ann Arbor in 1996, for which FTDP linked to chromosome 17 (FTDP-17) was the major focus. 1 Soon thereafter in 1998, mutations in MAPT were identified. 2 During the 8 years since this discovery, 41 mutations in MAPT have been found, 3 and many other issues relating to FTDP-17 due to mutations in MAPT have been characterized (Table 3) . 4 No sex predilection has been identified. The typical age of onset varies between 25 and 65 years. Penetrance appears to be close to 100%, though individuals living into old age without symptoms have been observed in families with at least 1 mutation (exon 10ϩ16). 2 The duration of symptoms from onset to death is typically 3 to 10 years. Symptomatology usually involves executive dysfunction and altered personality and behavior, with aphasia and parkinsonism evolving in many individuals. Memory impairment occurs less frequently as the primary presenting feature, and visuospatial impairment and limb apraxia are quite rare. Motor neuron Abbreviations: AD, Alzheimer disease; FTD, frontotemporal dementia; M = F, men and women inherit mutation equally; 0, no definite cases reported to date; ϩ, extremely rare; ϩϩ, infrequently reported; ϩϩϩ, frequently reported; ϩϩϩϩ, very frequently reported.
disease is also infrequent, though several cases have been reported. Most patients carry 1 or more of the syndromic diagnoses listed in Table 1 , particularly frontotemporal dementia (FTD) with or without parkinsonism, progressive nonfluent aphasia, or primary progressive aphasia. Rarely, the syndromes of mild cognitive impairment, probable Alzheimer disease, semantic dementia, or corticobasal syndrome are manifested. Few cases have been diagnosed with amyotrophic lateral sclerosis (ALS), and there are no reports of patients with mutations in MAPT who were diagnosed with posterior cortical atrophy or dementia with Lewy bodies. Over time, most patients develop other clinical features such that 2 or more syndromes can be applied, reflecting the progressively expanding involvement of other brain regions. 5 Structural neuroimaging studies show frontal and/or temporal atrophy, either symmetric or asymmetric 6 ; parenchymal signal changes on magnetic resonance imaging are either absent or very mild. 7 A similar topography of abnormalities is typically seen on singlephoton emission computed tomography and positron emission tomography scans, often with basal ganglia and/or thalamic hypoperfusion or hypometabolism. Pathologically, cortical atrophy is as indicated on imaging studies, with the maximally affected cortical gyri sometimes described as having a "knife edge" appearance. Tau-positive inclusions in neurons (eg, neurofibrillary tangles, neuronal threads, and Pick bodies) and/or glia (eg, astrocytic plaques and oligodendroglial coiled bodies) are always present on histologic examination, sometimes accompanied by argyrophilic grains. These tau-positive inclusions are often in a distribution such that patients would be pathologically identified as having corticobasal degeneration, progressive supranuclear palsy, argyrophilic grain disease, or Pick disease if the presence of an MAPT mutation was not known.
The mutations presumably cause disease either through disrupting the alternative splicing of MAPT exon 10 and thereby altering the relative levels of tau isoforms with 4 or 3 microtubule binding repeats, or they directly decrease the ability of tau to bind to and promote microtubule assembly and/or increase tau-filament formation. No disease-altering treatments exist yet for the tauopathies, though kinase inhibitors and microtubule tau stabilizers have shown promise in in vitro and animal model studies. 8, 9 A significant minority of patients with FTDP-17-many of whom were the focus of discussion at the meeting in Ann Arbor in 1996-had no identifiable mutations in MAPT, nor did they have any tau-positive inclusions at autopsy. [10] [11] [12] [13] The recent identification of mutations in PGRN in all of these remaining chromosome 17-linked families and in many other kindreds (Figure) 14-27 has now solved this decade-long conundrum, a few atypical FTDP phenotypes have been redefined, and an amazing freak of nature has been realized. The PGRN gene is only 1.7 Mb centromeric to MAPT on chromosome 17, demonstrating an intriguing example of how 2 apparently different genes can cause a very similar phenotype and reside so near to each other on the same chromosome. 27 With closer inspection, how similar are the clinical phenotypes associated with mutations in MAPT and PGRN? While our knowledge of the full spectrum of clinical, radiologic, and pathologic issues in FTDP associated with mutations in PGRN is still evolving, interesting findings have already emerged that allow comparisons between MAPT's and PGRN's mutation-associated characteristics (based on published findings to date and unpublished data from our group) ( Table 3 ). The frequency of mutations in PGRN in FTD series is similar to that in MAPT. 18 With at least 35 mutations identified to date, 3 almost as many mutations in PGRN have been discovered in less than 1 year than in the 8 years since the initial identification of mutations in MAPT. The mode of inheritance follows an autosomal dominant pattern but with reduced penetrance (only 90% of carriers develop symptoms by age 70 years). 18 There are multiple known PGRN mutation carriers who are asymptomatic in their 70s, and at least 1 known affected individual developed symptoms after age 80 years. The clinical features and particularly the syndromic diagnoses have been more variable than in MAPT mutation carriers, with not only behavioral and cognitive features commonly present, but also memory impairment, limb apraxia, parkinsonism, and visuospatial dysfunction, leading to cases being diagnosed with mild cognitive impairment, Alzheimer disease, Parkinson disease, Parkinson disease with dementia, and dementia with Lewy bodies in addition to FTD with or without parkinsonism and 1 of the progressive aphasia syndromes. 25 The diagnosis of corticobasal syndrome has also been particularly frequent in the cases reported thus far, while no patient with a definite pathogenic PGRN mutation has been reported to date with an ALS phenotype.
As one would expect, based on the clinical features of apraxia and visuospatial dysfunction, greater parietal involvement is clearly present in many PGRN mutation cases, which is also reflected on imaging and pathologic studies. In some cases, rather striking signal changes on magnetic resonance imaging are present, 25 which is rarely seen in MAPT mutation carriers. Another curious observation is the tendency in some kindreds for the same cerebral hemisphere to be maximally involved in most or all affected members of a family, such as a progressive aphasia syndrome with maximal left hemisphere involvement 22, 26, 28 and the corticobasal syndrome with or without FTD features with maximal right hemisphere involvement 25, 29 ; to our knowledge, this tendency has not been noted among any kindreds with MAPT mutations.
On histologic examination, the consistent finding is FTLD with ubiquitin-positive inclusions with neuronal intranuclear inclusions. 14, [16] [17] [18] [20] [21] [22] [23] [24] [25] [26] Immunostaining directed against progranulin stain normal structures within neurons and activated microglia. However, the ubiquitinated inclusions are not progranulin immunoreactive; rather, transactive response DNA-binding protein 43 was very recently discovered to be a major ubiquitinated protein in both neuronal cytoplasmic and intranuclear inclusions in PGRN mutation cases. 30 Moreover, transactive response DNA-binding protein 43 is also present in neuronal ubiquitin-positive inclusions in FTLD with ubiquitin-positive inclusions, FTLD with motor neuron disease, and idiopathic ALS. 31 Also contrasting with MAPT is the mechanism of disease with PGRN mutations-all PGRN mutations identified thus far create functional null alleles that cause a partial reduction in progranulin production or haploinsufficiency. 14, 16, 18 This disease mechanism may allow a more straightforward approach for treatment by either replacing progranulin or using drugs to increase production or secretion of progranulin from the remaining normal PGRN allele.
The net effect of 2 genes linked not only by proximity but also by most overlapping and expanding features requires refinements in our conceptual framework and nomenclature in FTDP. An obvious solution to this problem is to simply refine the term by including reference to the genetic cause of the disease in each case, and thus FTDP-17 could be subdivided into FTDP-17 (MAPT) and FTDP-17 (PGRN). This approach has the advantage of employing a now widely used, if not always completely appropriate, clinical terminology, refining it to reflect that ultimately these conditions are defined by their genetics rather than their clinical or pathological phenotypes. The scientific community has clearly just begun to expand the characterization and refine the nomenclature of familial disorders linked to chromosome 17.
